International Cannabinoid Derived Pharmaceuticals Summit

International Cannabinoid Derived Pharmaceuticals Summit

Hanson Wade 10/12/2018 to 12/12/2018 | USA, Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, 02111
+1 2125375898

With 17+ hours of content, we will be tackling the key issues from the benchside to commercialization. By considering a range of therapeutic areas, the conference is designed exclusively for the Cannabinoid drug developer. Our speakers will discuss complex Cannabinoid pharmacology, formulations, clinical trials, patient education and commercial challenges.

URL:

Tickets: https://go.evvnt.com/267417-0?pid=5179

Time: 8:00 am - 6:00 pm

Prices:

Conference Only: GBP 1999.0,

Conference + 2 Workshops: GBP 2897.0

Speakers: Chris Bunka, Chairman of the Board and Chief Executive Officer, Lexaria Biosciences, Tamás Biro, Professor, Research Center for Molecular Medicine Departments of Immunology and Physiology, University of Debrecen, Le Roy Dowey, Head of Corporate Development, Greenlight Medicines, Vincenzo di Marzo, Canada Excellence Research Chair, Université Laval and Research Director, CNR, Sazzad Hossain, CEO Entourage Biosciences / CSO, Inmed Pharmaceuticals Inc, Allyn Howlett, Professor, Wake Forest University, Gary Hiller, Chief Operations Officer and President, Phytecs, Catherine Jacobson, Director of Clinical Research, Tilray, Zohar Koren, Chief Executive Officer and Founder, SciCann, Shimon Lecht, Chief of Research and Development CannRx, Arnold Lippa, Executive Chairman and Chief Scientific Officer, RespireRx Pharmaceuticals, Jeff Eliot Margolis, Senior Vice President, Chief Financial Officer, Treasurer, Secretary, member of the Board of Directors, RespireRx Pharmaceuticals, Soumyajit Majumdar, Professor of Pharmaceutics and Drug Delivery, University of Mississippi, Brian Murphy, Chief Executive Officer and Chief Medical Officer, Nemus Bioscience, Inc, Richard Purcell, Senior Vive President, RespireRx, Dan Peer, Chair, Tel Aviv University Cancer Biology Research Center; Managing Director, Center for Translational Medicine, Jutta Roth, Chief Scientific Officer, Oxford Cannabinoid Technologies, Andrea Small- Howard, Chief Scientific Officer, GB Sciences, Adi Zulloff-Shani, Chief Technology Officer, Therapix

more
page up